skip to content »

Neurology

Houston, Texas

The Cullen Building at Baylor College of Medicine.
Department of Neurology
not shown on screen

George J. Hutton, M.D.

Associate Professor of Neurology

Medical Director, Maxine Mesinger MS Comprehensive Care Center

Clinical Service Area

Neurology

Specialty

Demyelinating Diseases
General Neurology
Optic Neuritis
Multiple Sclerosis

Board Certification

American Board of Psychiatry and Neurology, Neurology

Clinic Appointments

713-798-8170

Consult

713-798-8170

Medical School

M.D., Vanderbilt University School of Medicine, Nashville, Tenn.

Internship

Internal Medicine, Baylor College of Medicine, Houston, Texas

Residency

Neurology, Baylor College of Medicine, Houston, Texas

Clinical Fellowship

Multiple Sclerosis, Baylor College of Medicine, Houston, Texas

Clinic Location

Maxine Mesinger MS Comprehensive Care Center
Neurosensory Building
6501 Fannin, NB100
Houston, Texas 77030

Clinical Interests

Multiple sclerosis and other demyelinating diseases of the central nervous system (adult and pediatric), neurologic complications of pregnancy, neurologic complications after bone marrow transplantation

Contact Information

George J. Hutton, M.D.
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-8170
Fax: 713-798-0115

BCM Honors

  • 2008 Fulbright & Jaworski LLP Faculty Excellence Award for Teaching and Evaluation and has become a member of the Academy of Distinguished Educators, which recognizes the educational scholarship of faculty members involved in all of the educational missions of Baylor College of Medicine.

Journal Publications (Selected out of 20)

  • Helekar SA, Shin JC, Mattson BJ, Bartley K, Stosic M, Saldana-King T, et al. Functional brain network changes associated with maintenance of cognitive function in multiple sclerosis. Front Hum Neurosci. 2010;4:219. [View journal article]
  • Hong J, Hutton GJ. Regulatory effects of interferon-beta on osteopontin and interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):751-7. [View journal article]
  • Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL, et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology. 2009;72(6):535-541. [View journal article]
  • Brodsky M, Orengo-Nania S, Hutton GJ, Slight B, Buckley EG, Massey EW, et al. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115(6):1079-1082 e5. [View journal article]
  • Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics. 2008;122(5):e1039-47. [View journal article]
  • Zhang J, Hutton G. Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. Annu Rev Med. 2005;56:273-302. [View journal article]
  • Bakshi R, Hutton GJ, Miller JR, Radue EW. The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology. 2004;63(11 Suppl 5):S3-11. [View journal article]
  • Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004;152(1-2):126-39. [View journal article]
  • Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004;127(Pt 5):996-1008. [View journal article]
  • Zang YC, Skinner SM, Robinson RR, Li S, Rivera VM, Hutton GJ, et al. Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by interferon beta in multiple sclerosis. Mult Scler. 2004;10(5):499-506. [View journal article]

Book Chapters and Other Publications

  • Zhang J, Hutton G. Therapeutic targets for the treatment of multiple sclerosis. In: Columbus F, editor. Treatment and management of multiple sclerosis. New York: Nova Biomedical Books; 2005. p. 107-153.
  • Hutton G, Oyama Y, Burt RK, Popat U. Hematopoietic stem cell transplantation in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. In: Burt RK, Marmont AM, editors. Stem cell therapy for autoimmune diseases. Georgetown (TX): Landes Bioscience; 2004. p. 419-428.
  • Hutton GJ. Demyelinating and inflammatory diseases of the central nervous system. In: Poolos N, editor. Handbook of differential diagnosis in neurology. Boston: Butterworth-Heinemann; 2001. p. 63-79.

Poster and Platform Presentations (Selected out of 50)

  • Dragan E, Hutton G, Birnbaum Y. Case series of cardiac complications during fingolimod first dose observation period. Presented at the Consortium of Multiple Sclerosis Centers (CMSC), 27th Annual Meeting in Orlando, Fla. (May 29 - June 1, 2013). [View poster]
  • Dragan E, Hutton G. Neuromyelitis optica presenting as multiple sclerosis worsening on natalizumab. Presented at the Consortium of Multiple Sclerosis Centers (CMSC), 27th Annual Meeting in Orlando, Fla. (May 29 - June 1, 2013). [View poster]
  • Dragan E, Hutton G. Treatment of idiopathic relapsing transverse myelitis. Presented at the Consortium of Multiple Sclerosis Centers (CMSC), 27th Annual Meeting in Orlando, Fla. (May 29 - June 1, 2013). [View poster]
  • Dragan E, Saldana-King T, Hutton G. Efficacy of fingolimod in ethnic minorities. Presented at the Consortium of Multiple Sclerosis Centers (CMSC), 27th Annual Meeting in Orlando, Fla. (May 29 - June 1, 2013). [View poster]
  • Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Georges GE, et al. Two-year follow-up results of the HALT MS clinical trial (ITN033AI). Presented at the Consortium of Multiple Sclerosis Centers (CMSC), 27th Annual Meeting in Orlando, Fla. (May 29 - June 1, 2013).
  • Dragan E, Hutton G. Treatment of idiopathic relapsing transverse myelitis. Neurology. 2013;80(Meeting Abstracts 1):P02.124. [View poster]
  • Thrower B, Yapundich R, Applebee A, Hutton G, Klingler M, Henney H, et al. Safety and efficacy of 5 mg and 10 mg dalfampridine extended release tablets in patients with multiple sclerosis: First results from a double-blind, placebo-controlled trial. Neurology. 2013;80(Meeting Abstracts 1):P04.096. [View poster]
  • Stosic M, De Jesus P, McCarthy J, Hutton GJ, Rivera VM. Multiple sclerosis patient treated with natalizumab develops immune thrombocytopenic purpura. Presented at the Baylor College of Medicine (BCM), Current Neurology 2012 in Houston, Texas (Nov. 3-4, 2012). [View poster]
  • Avila M, Prieto P, Avila-Ornelas J, Stosic M, Amin A, Hutton GJ, et al. Distal limb discoloration in patients with multiple sclerosis - Case series of 41 patients. Neurology. 2011;76(Suppl 4):A290. [View poster]
  • Qiu C, Avila M, Hutton G. Incidence of multiple sclerosis in patients presenting with neurogenic bladder. Neurology. 2011;76(Suppl 4):A600. [View poster]

E-mail this page to a friend